The IL-1 receptor antagonist (IL-1Ra), a selective and natural competitive inhibitor of IL-1, holds promise as an innovative treatment for stroke, as it can reduce infarct volume and improve long-term functional outcomes in experimental stroke models (Pradillo et al., 2017). This evidence concerns the gene IL1B and stroke disorder.